Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022
Arthritis & Rheumatology · 2024
DOI: 10.1002/art.42963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Eric T Roberts und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco. Hauptthemen laut MEDLINE: Infliximab, Medicaid, Biosimilar Pharmaceuticals, Medicare. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, AHRQ HHS, American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry.
Abstract (Originalsprache)
Objective
Biosimilars have the potential to reduce spending on biologic drugs, yet uptake has been slower than anticipated. We investigated how successive introductions of infliximab biosimilars influenced their adoption by major US insurance providers.
Methods
Data came from the Rheumatology Informatics System for Effectiveness, a national registry with electronic health records from more than 1,100 US rheumatologists. All infliximab administrations (bio‐originator or biosimilar) to patients aged ≥18 years from April 2016 to September 2022 were included. We used an interrupted time series to model the effect of each infliximab biosimilar release (infliximab‐dyyb, November 2016; infliximab‐adba, July 2017; and infliximab‐axxq, July 2020) on uptake across Medicare, Medicaid, and private insurers.
Results
With the first and second biosimilar releases, biosimilar uptake rose slowly, with average annual increases of ≤5% from 2016 to June 2020 (Medicare 3.2%, Medicaid 5.2%, and private insurance 1.8%). With the third biosimilar release in July 2020, the average annual increase reached 13% for Medicaid and 16.4% for private insurance but remained low for Medicare (5.6%). By September 2022, uptake was higher for Medicaid (43.8%) and private insurance (38.5%) than for Medicare (24%).
Conclusion
Our results have two key findings for policy makers. First, our results suggest that one or two biosimilars may not generate enough competition to speed adoption rates for biosimilars. Second, Medicare, which covers most patients receiving biologics nationally, had slow adoption rates even after the third biosimilar was introduced. Policy levers to speed adoption among Medicare beneficiaries are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, San Francisco.
- University of British Columbia, Vancouver, British Columbia, Canada.
- University of Hawai'i John A. Burns School of Medicine, Honolulu.
- University of California, San Francisco and San Francisco Veterans Affairs Medical Center.
- University of California, San Francisco and Zuckerberg San Francisco General Hospital.
ORCID-Profile: Eric T Roberts, Jing Li, Gabriela Schmajuk, Jinoos Yazdany
Förderung
- NIAMS NIH HHS
- AHRQ HHS
- American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Agency for Healthcare Research and Quality
Zitieren
APA
Roberts, E. T., Li, J., Bansback, N., Tseng, C. W., Shiboski, S., Schmajuk, G., & Yazdany, J. (2024). Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022. Arthritis & Rheumatology. https://doi.org/10.1002/art.42963
Vancouver
Roberts ET, Li J, Bansback N, Tseng CW, Shiboski S, Schmajuk G, et al. Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022. Arthritis & Rheumatology. 2024. doi:10.1002/art.42963
BibTeX
@article{Roberts2024,
author = {Roberts, Eric T and Li, Jing and Bansback, Nick and Tseng, Chien-Wen and Shiboski, Steve and Schmajuk, Gabriela and Yazdany, Jinoos},
title = {Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022},
journal = {Arthritis & Rheumatology},
year = {2024},
doi = {10.1002/art.42963}
}
EUVIMED